SB 950 adds qualifying dementia treatment coverage protections
Oct 4, 2026 edition · GC-2026-0244 · Published 2026-10-04 · Version 2 · Final
SB 950 establishes 2027 coverage and step-therapy protections for qualifying FDA-approved memory treatments, with specified exceptions.
What happened
California approved and filed SB 950 on September 27. Affected contracts and policies issued, amended or renewed on or after January 1, 2027 must cover medically necessary FDA-approved treatments or medications for Alzheimer’s disease or other conditions affecting memory, as determined by a health care provider. The protection reaches medical benefits and outpatient prescription benefits to the extent that outpatient drugs are covered. From January 1, step therapy is restricted for both self-administered and physician-administered treatments, but the statute does not require every treatment type to be available without it if at least one antiamyloid therapy is covered without step therapy.
Other utilization management, including prior authorization, remains permissible to determine medical necessity if applied in the same manner as for other covered illnesses. Coverage criteria may not be more restrictive than the FDA-approved indications, and qualifying authorization is treated as an exigent circumstance under the referenced review rules. The plan provisions exclude dental- or vision-only specialized plans, Medicare supplements and Medi-Cal managed care; the insurance section also lists limited-benefit policy exclusions. As of October 4, the January contract milestone calls for product and benefit preparation, while clinical eligibility and the specific step-therapy exception remain central to any individual request.
Scope and timing
- Authority status
- Final
- Applicability
- Potentially applicable
- Audience
- Health systems, Provider networks, Health-tech
- Jurisdiction
- California
- Affected functions
- Managed Care, Compliance, Clinical Operations
- Responsible owner
- Managed Care
- Recorded date
- 2027-01-01
- Date type
- implementation
Why it matters
Neurology and pharmacy pathways need coordinated medical and drug benefit rules, expedited authorization handling and a properly scoped step-therapy design.
Recommended action
Identify affected 2027 contracts and antiamyloid access, review FDA-indication criteria and exigent authorization routing, and preserve lawful medical-necessity review and statutory product exclusions.
Implementation playbook
- Confirm affected members, benefits and contracts against the final statutory scope. Managed Care · Due 2026-10-18
- Confirm covered contracts, FDA criteria and antiamyloid access; retain lawful review and member-specific medical necessity. Compliance · Due 2027-01-01
- Validate updated workflows, communicate changes and monitor implementing guidance. Compliance · Due 2027-01-01
Sources
- SB950 enacted final textOfficial · California Legislature · 2026-09-27 · Source review 2026-10-05
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Medicare & Medicaid report →